ClinicalTrials.gg
CompletedNCT02243293Updated Jul 30, 2021Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

A Phase 2/3 interventional study of ABT-493 and ABT-530 in Chronic Hepatitis C and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
694
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Hepatitis C, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · AbbVie.

Enrollment
3rd of 58
694 · median 144
Started
2014
with 10 others
Phase 2/3
5 of 83
none open now
Registered
25th of 83
by date

Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 3rd largest by enrollment of the 58 interventional ones that give a count, is one of 11 that started in 2014, is one of 5 in phase 2/3, and was the 25th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies in Hepatitis C, Chronic by AbbVie is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies in Hepatitis C, Chronic by AbbVie as a file.
02

Study summary

The purpose of this phase 2/3, open-label, multipart, multicenter study was to evaluate the efficacy, and safety of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) in chronic HCV genotype 2 (GT2-), genotype 3 (GT3-), genotype 4 (GT4), genotype 5 (GT5-), or genotype 6 (GT6-) infected participants with or without cirrhosis.

Read the detailed description

The study consisted of four independent parts with treatment and post-treatment periods of enrollment. Parts 1 and 2 were the supportive/ exploratory parts (phase 2) of the study and part 3 and 4 were the confirmatory/ registrational parts (phase 3) of the study. In parts 1 and 2 of the study, ABT-493 and ABT-530 were co-administered as separate tablets. However, in parts 3 and 4 of the study, the ABT-493/ABT-530 co-formulated tablets were administered.

03

Conditions studied

  • Chronic Hepatitis C
  • Hepatitis C Virus

Keywords

  • Hepatitis C Virus (HCV)
  • Hepatitis C
  • Chronic Hepatitis C
  • interferon free
  • Hepatitis C Genotype 2
  • Hepatitis C Genotype 3
  • Hepatitis C Genotype 4
  • Hepatitis C Genotype 5
  • Hepatitis C Genotype 6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening laboratory result indicating Genotype 2, 3, 4, 5, or 6 infection.
  • Chronic HCV infection.
  • Participant had to be either HCV treatment-naïve or treatment-experienced.
  • Participant had to be documented as non-cirrhotic or as having compensated cirrhosis (GT3 only).

Exclusion criteria

Exclusion Criteria:

  • History of severe, life-threatening or other significant sensitivity to any drug.
  • Female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study.
  • Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.
  • Positive test result at Screening for surface antigen (HBsAg) or anti- antibody (HIV Ab).
  • genotype performed during screening indicating co-infection with more than one HCV genotype.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
694 participants (actual)

Study arms

  • Experimental
    Arm A

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm B

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm C

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)

  • Experimental
    Arm D

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm E

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm F

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)

  • Experimental
    Arm G

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm H

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm I

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm J

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm K

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm L

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm M

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm N

    ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.

    Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)

  • Experimental
    Arm O

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.

    Drug: ABT-493 · Drug: ABT-530

  • Experimental
    Arm P

    ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.

    Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)

  • Experimental
    Arm Q1

    ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm Q2

    ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm R1

    ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm R2

    ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm S1

    ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493/ABT-530

  • Experimental
    Arm S2

    ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.

    Drug: ABT-493/ABT-530

Interventions

  • Tablet

    Also known as: glecaprevir

  • Tablet

    Also known as: pibrentasvir

  • Tablet

  • DrugABT-493/ABT-530

    Drug page: Glecaprevir and pibrentasvir

    Tablet; ABT-493 co-formulated ABT-530

    Also known as: ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of study drug

  2. Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)

    SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.

    Time frame: 4 weeks after the last actual dose of study drug

  2. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.

    Time frame: Up to end of treatment (treatment week 8, 12 or 16 depending on arm) or premature discontinuation from treatment

  3. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.

    Time frame: From the end of treatment through 12 weeks after the last dose of study drug

07

Results

Posted Oct 2, 2017

Participant flow

Enrollment into arms H, I, K, M and N was not opened by AbbVie.

Participant flow — Overall Study
MilestoneArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm KArm LArm MArm NArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2
Started2524253031313000550530028274022224814558
Completed2323242930312700530500027263721224714355
Not completed2111103002030011310123
Withdrew: Adverse event1000000000000001000010
Withdrew: Withdrawal by subject1000000001010000000001
Withdrew: Lost to follow-up0111003000020000310012
Withdrew: Enrolled into a re-treatment study0000000000000010000000
Withdrew: Randomized but did'nt receive study drug0000100001000000000100

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)96.0 (80.5 to 99.3)100.0 (86.2 to 100.0)100.0 (86.7 to 100.0)93.3 (78.7 to 98.2)93.3 (78.7 to 98.2)93.5 (79.3 to 98.2)83.3 (66.4 to 92.7)98.1 (90.2 to 99.7)94.3 (84.6 to 98.1)96.4 (82.3 to 99.4)100.0 (87.5 to 100.0)97.5 (87.1 to 99.6)90.9 (72.2 to 97.5)95.5 (78.2 to 99.2)95.7 (85.8 to 98.8)97.9 (94.1 to 99.3)93.1 (83.6 to 97.3)
PrimaryPercentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control
percentage of participantsArm S1
Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control98.5 (96.5 to 100.0)
Statistical analysis
  • Arm S1 · Percentage of participants: 98.5 · 95% CI 96.5 to 100.095% CI was calculated using the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)

SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.

Time frame:
4 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2
Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)96.0 (80.5 to 99.3)100.0 (86.2 to 100.0)100.0 (86.7 to 100.0)93.3 (78.7 to 98.2)93.3 (78.7 to 98.2)93.5 (79.3 to 98.2)93.3 (78.7 to 98.2)98.1 (90.2 to 99.7)96.2 (87.2 to 99.0)96.4 (82.3 to 99.4)100.0 (87.5 to 100.0)97.5 (87.1 to 99.6)95.5 (78.2 to 99.2)95.5 (78.2 to 99.2)95.7 (85.8 to 98.8)97.9 (94.1 to 99.3)98.3 (90.9 to 99.7)
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.

Time frame:
Up to end of treatment (treatment week 8, 12 or 16 depending on arm) or premature discontinuation from treatment
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2
Percentage of Participants With On-treatment Virologic Failure0 (0.0 to 13.3)0 (0.0 to 13.8)0 (0.0 to 13.3)0 (0.0 to 11.4)0 (0.0 to 11.4)3.2 (0.6 to 16.2)3.3 (0.6 to 16.7)0 (0.0 to 6.6)1.9 (0.3 to 9.9)0 (0.0 to 12.1)0 (0.0 to 12.5)0 (0.0 to 8.8)0 (0.0 to 14.9)0 (0.0 to 14.9)2.1 (0.4 to 11.1)0 (0.0 to 2.6)0 (0.0 to 6.2)
SecondaryPercentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.

Time frame:
From the end of treatment through 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2
Percentage of Participants With Post-treatment Relapse0.0 (0.0 to 13.8)0.0 (0.0 to 13.8)0.0 (0.0 to 13.3)3.4 (0.6 to 17.2)6.7 (1.8 to 21.3)0.0 (0.0 to 12.1)7.1 (2.0 to 22.6)0.0 (0.0 to 6.8)2.0 (0.3 to 10.3)3.6 (0.6 to 17.7)0.0 (0.0 to 12.5)0 (0.0 to 9.0)9.1 (2.5 to 27.8)4.5 (0.8 to 21.8)2.2 (0.4 to 11.3)1.4 (0.4 to 4.9)0 (0.0 to 6.3)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 20 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARM A1/25 (4%)0/25 (0%)12/25 (48%)
ARM B0/24 (0%)0/24 (0%)11/24 (45.8%)
ARM C0/25 (0%)1/25 (4%)22/25 (88%)
ARM D0/30 (0%)0/30 (0%)19/30 (63.3%)
ARM E0/30 (0%)0/30 (0%)20/30 (66.7%)
ARM F0/31 (0%)2/31 (6.5%)23/31 (74.2%)
ARM G0/30 (0%)0/30 (0%)18/30 (60%)
ARM J0/54 (0%)1/54 (1.9%)26/54 (48.1%)
ARM L0/53 (0%)1/53 (1.9%)40/53 (75.5%)
ARM O0/28 (0%)2/28 (7.1%)20/28 (71.4%)
ARM P1/27 (3.7%)2/27 (7.4%)21/27 (77.8%)
ARM Q10/40 (0%)1/40 (2.5%)30/40 (75%)
ARM Q20/22 (0%)1/22 (4.5%)12/22 (54.5%)
ARM R10/22 (0%)1/22 (4.5%)13/22 (59.1%)
ARM R20/47 (0%)3/47 (6.4%)31/47 (66%)
ARM S11/145 (0.7%)1/145 (0.7%)78/145 (53.8%)
ARM S20/58 (0%)1/58 (1.7%)32/58 (55.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventARM AARM BARM CARM DARM EARM FARM GARM JARM LARM OARM PARM Q1ARM Q2ARM R1ARM R2ARM S1ARM S2
SchizophreniaPsychiatric disorders0/250/240/250/300/300/310/300/540/530/280/270/401/220/220/470/1450/58
Pleural effusionRespiratory, thoracic and mediastinal disorders0/250/240/250/300/300/310/300/540/530/280/270/400/221/220/470/1450/58
Atrial fibrillationCardiac disorders0/250/241/250/300/300/310/300/540/530/280/270/400/220/220/470/1450/58
AnaemiaBlood and lymphatic system disorders0/250/240/250/300/300/310/300/540/530/281/270/400/220/220/470/1450/58
Delusional disorder, unspecified typePsychiatric disorders0/250/240/250/300/300/310/300/540/530/281/270/400/220/220/470/1450/58
Tibia fractureInjury, poisoning and procedural complications0/250/240/250/300/300/310/300/540/531/280/270/400/220/220/470/1450/58
Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/240/250/300/300/310/300/540/531/280/270/400/220/220/470/1450/58
PneumoniaInfections and infestations0/250/240/250/300/301/310/300/540/530/280/270/400/220/220/470/1450/58
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/240/250/300/301/310/300/540/530/280/270/400/220/220/470/1450/58
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/240/250/300/300/310/300/540/530/280/271/400/220/220/470/1450/58
Most frequent other events
Showing 10 of 63
Most frequent other events
EventARM AARM BARM CARM DARM EARM FARM GARM JARM LARM OARM PARM Q1ARM Q2ARM R1ARM R2ARM S1ARM S2
FatigueGeneral disorders2/253/2410/256/305/3012/312/307/5415/533/288/275/404/224/2216/4724/14513/58
NauseaGastrointestinal disorders3/251/248/252/306/3011/310/305/544/533/287/274/402/222/225/4718/1455/58
HeadacheNervous system disorders1/253/246/254/303/306/315/306/5417/535/289/2710/405/224/226/4717/14511/58
DiarrhoeaGastrointestinal disorders4/251/246/252/301/302/312/304/548/536/281/274/401/222/221/474/1452/58
Upper respiratory tract infectionInfections and infestations1/251/245/254/301/301/311/301/544/535/282/273/401/220/222/4710/1453/58
InsomniaPsychiatric disorders0/250/242/251/302/303/311/303/545/530/285/271/400/220/223/471/1452/58
Back painMusculoskeletal and connective tissue disorders1/250/240/251/301/300/312/303/541/530/283/274/400/224/220/476/1452/58
DizzinessNervous system disorders2/250/240/251/301/305/310/300/541/532/284/274/401/220/221/477/1452/58
SinusitisInfections and infestations1/250/244/251/302/301/310/300/541/531/281/270/400/220/220/473/1450/58
Haemoglobin decreasedInvestigations0/250/244/250/300/304/310/300/540/530/282/270/400/220/220/470/1450/58

Baseline characteristics

All participants who received atleast 1 dose of study drug (ITT population)

Age, Customized
Age, Customized(participants)Arm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2Total
< 65 years21212228293028445226243818193912849616
>= 65 years433211210123243817975
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2Total
Female91171116121521211391688118421293
Male1613181914191533321518241414366137398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BArm CArm DArm EArm FArm GArm JArm LArm OArm PArm Q1Arm Q2Arm R1Arm R2Arm S1Arm S2Total
Hispanic or Latino12443556242910411265
Not Hispanic or Latino24222126272625485124253121224313456626
Unknown or Not Reported000000000000000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13. PubMed 28412293 ↗
  • Brown A, Welzel TM, Conway B, Negro F, Brau N, Grebely J, Puoti M, Aghemo A, Kleine H, Pugatch D, Mensa FJ, Chen YJ, Lei Y, Lawitz E, Asselah T. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. Liver Int. 2020 Apr;40(4):778-786. doi: 10.1111/liv.14266. Epub 2019 Oct 18. PubMed 31568620 ↗
  • Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat. 2019 Aug;26(8):951-960. doi: 10.1111/jvh.13110. Epub 2019 May 20. PubMed 30977945 ↗
  • Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Worns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis. 2019 Oct 30;69(10):1657-1664. doi: 10.1093/cid/ciz022. PubMed 30923816 ↗
  • Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, Bourliere M, Calleja JL, Kosloski MP, Oberoi RK, Lin CW, Yu Y, Lovell S, Semizarov D, Mensa FJ. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10. PubMed 30012435 ↗
  • Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22. PubMed 28951228 ↗
  • Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 Oct;151(4):651-659.e1. doi: 10.1053/j.gastro.2016.07.020. Epub 2016 Jul 25. PubMed 27456384 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Oct 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 11 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2014
First posted
Sep 17, 2014
Start
Sep 19, 2014
Primary completionActual
Oct 25, 2016
CompletionActual
Feb 23, 2017
Results delay requested
Feb 8, 2017
Results first posted
Oct 2, 2017
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02243293
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Sep 19, 2014
Primary completion
Oct 25, 2016
Completion
Feb 23, 2017
Results posted
Oct 2, 2017
Last update
Jul 30, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glecaprevir · Pibrentasvir · Ribavirin · Glecaprevir and pibrentasvir

Start the discussion